Cannasouth is a biopharmaceutical research and development company based in the Waikato heartland of New Zealand. The Company has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds such as CBD, THC and associated chemical structures that are produced by the cannabis plant. Their goal is the development of next-generation cannabinoid medicines that support patients’ health outcomes and improve their quality of life. Their products will be produced under GMP & ISO using environmentally friendly methods without the use of harmful chemicals or solvents, ensuring patients are treated with pure cannabinoid therapeutic compounds of the highest quality.

Biotechnology

Cannasouth

David Gill

Pierre Booysen

Greg Misson

Cannasouth's Leadership Team includes Colin Foster and 5 others.

Leadership Team

About

Team members